Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Meiji, Fujirebio Terminate Joint Sales Agreement
April 11, 2011
- Korosho Calls For Restraint in Use of EN Products Due to Shortage of Ensure
April 11, 2011
- Looking Back Over a Hectic Week for Vaccines
April 4, 2011
- Prazaxa to Mainly Target CV Specialists, Neurologists: NBI
April 4, 2011
- NIBIO to Promote Development of Next-generation Adjuvants
April 4, 2011
- New Drugs May Be Approved 1 Month Earlier from April
April 4, 2011
- Kitasato Daiichi Sankyo Vaccine Co., Ltd. Inaugurated
April 4, 2011
- Restrictions on Ex-company Employees of PMDA to Remain for Now
April 4, 2011
- Tokyo District Court Holds Both Gov't, AZ Responsible in Iressa Affair
April 4, 2011
- Takeda Applies for Novel ARB Azilsartan in Japan
April 4, 2011
- ASKA Resumes Production, Shipment of Thyradin-S Tablets
April 4, 2011
- Daiichi Sankyo's Direct Xa Inhibitor Rixiana Recommended for Approval by PAC
April 4, 2011
- Damage at Fukushima Plant to Affect 3 Brands: Ajinomoto Pharm.
April 4, 2011
- Eisai Announces Approval of Halaven in Europe
April 4, 2011
- Daiichi Sankyo Resumes Production at Some Facilities
April 4, 2011
- Fingolimod Approved for MS in Europe: Novartis
April 4, 2011
- Shipments of Ensure to Resume in Late May: Abbott Japan
April 4, 2011
- CHMP to Assess Benefit-Risk Balance of Pioglitazone
April 4, 2011
- Asahi Kasei Licenses XIAFLEX from Auxilium
April 4, 2011
- MREAC Calls For “Consideration”in Post-disaster MR Activities
April 4, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…